|
Video: What is a Stock Split?
|
|
Dicerna Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that are designed to utilize ribonucleic acid interference to silence selectively genes that cause or contribute to disease. Nedosiran is Co.'s investigational product candidate for the treatment of primary hyperoxaluria (PH) type 1, PH type 2, and PH type 3. Co.'s GalXC product candidate, RG6346, is for the treatment of chronic hepatitis B virus (HBV) infection. Therapies for HBV include nucleoside analogs and pegylated interferon regimens. Co.'s another GalXC product candidate, belcesiran, is for the treatment of alpha-1 antitrypsin deficiency-associated liver disease. According to our DRNA stock split history records, DRNA has had 0 splits. | |
|
DRNA (DRNA) has 0 splits in our DRNA stock split history database.
Looking at the DRNA stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into DRNA shares, starting with a $10,000 purchase of DRNA, presented on a split-history-adjusted basis factoring in the complete DRNA stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
12/28/2021 |
|
Start price/share: |
$17.78 |
|
End price/share: |
$38.22 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
114.96% |
|
Average Annual Total Return: |
10.46% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$21,491.39 |
|
Years: |
7.69 |
|
|
|
|
|